Skip to main content
Premium Trial:

Request an Annual Quote

PGXL Labs Adopts AutoGenomics' Infiniti System for Warfarin, CYP450 Testing


This story was originally posted on April 1.

PGXL Laboratories will offer warfarin and CYP450 2C19 testing on AutoGenomics' Infiniti system, the companies announced this week.

PGXL, a Louisville, Ky.-based pharmacogenomics services provider, also plans to introduce other AutoGenomics assays, such as its KRAS-BRAF test, in the future.

PGXL offers pharmacogenetic testing and interpretive services in its US Clinical Laboratory Improvement Acts-compliant facility. It also performs contract research for manufacturers of pharmaceuticals and medical equipment.

AutoGenomics' Infiniti platform makes use of the Vista, Calif.-based firm's BioFilmChip microarray technology, which consists of multiple layers of hydrogel matrices about 10 µm thick on a polyester solid support. AutoGenomics' warfarin and CYP450 2C19+ tests, in addition to several others, have been cleared by the US Food and Drug Administration for clinical use. The company is discussing additional submissions with the agency, including its KRAS and BRAF assay (BAN 1/25/2011).

Mark Linder, executive vice president of operations at PGXL, cited AutoGenomics' "comprehensive menu of molecular applications in the pharmacogenetics arena" as a reason why the testing company adopted the Infiniti platform.

Ram Vairavan, senior vice president of AutoGenomics, said that its array technology "allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests."

Further details of the deal were not discussed.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.